Under such circumstances, there are several reports on the efficacy of the tyrosine kinase inhibitor gefitinib in patients with epidermal growth factor receptor (EGFR) gene mutations[23,24], and this molecularly targeted therapy is likely to improve the prognosis of cases with progressive high grade and recurrent MEC. The gene discussed is EGFR; the disease is mucoepidermoid carcinoma.